Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cyclophosphamide as graft-versus-host prophylaxis after allogeneic stem cell transplantation in high-risk multiple myeloma
2016-002557-38Phase 2Completed
- Sponsor
- University Medical Center Hamburg-Eppendorf
- Start
- Oct 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cyclophosphamide in multiple myeloma (MM), sponsored by University Medical Center Hamburg-Eppendorf. Started Oct 2017; status: completed.
02
Drugs
cyclophosphamide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2016-002557-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002557-38.